Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete · 1983
[Drug therapy of hyperprolactinemia, acromegaly and Cushing syndrome].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marek J, Rezábek K, Srámková J
Аннотация
39 patients with hyperprolactinaemia (32 adenomas of the pituitary gland, 7 idiopathic hyperprolactinaemias) were treated with the ergot derivative Lisurid. In 3 patients side-effects appeared which did not allow an increase to the therapy-effective dose. In all other patients with a dose of 0.075 to 6 mg Lisurid a day a normalisation of the prolactinaemia was achieved. A pregnancy appeared in 15 of 16 women who wished a child. In 4 men with normal gonadotropic reserve libido, potency and plasma testosterone normalised after the treatment with Lisurid. In addition of Lisurid also other ergot derivatives with prolactin-inhibiting effect, such as dironyl, deprenone and propyldeprenone were tested. Here dironyl has an advantage showing less side-effects and no changes of blood pressure. The ergot derivatives may be used also in the treatment of acromegaly. In 7 of 21 patients with acromegaly who were treated a longer time we succeeded in reducing the level of the growth hormone below 50%, in 2 patients the condition completely normalised. On the other hand, a normalisation of the somatomedin level appeared only in 11 of 21 patients. Patients with central Cushing's disease only exceptionally react to the treatment with ergot derivatives.